Perihematomal Cerebral Tissue XXXX Quantification on MRI Following Intracerebral @entity548 in Two @entity1 Subjects: Proof of Principle.

@entity1 @entity64 @entity932 @entity548 @entity16 @entity2359 @entity1410 @entity68
Spontaneous @entity932 ( @entity932 ) is a common @entity64 subtype with significant @entity16 . The management of @entity932 is usually supportive treatment in the neuro-intensive care setting, while the body humors deal with the @entity1410 . Treatment of the @entity1410 is usually expectant management unless there is @entity16 caused by mass effect from the @entity548 . Some minimally invasive techniques have been explored for lysing and evacuating the @entity1410 , but none of them have gained a stronghold in the routine clinical management of this condition. Studies mainly in animal (rodent and porcine) @entity932 models have shown the role of bound and unbound @entity68 in causing @entity2359 following an @entity932 . There is currently no noninvasive method for assessing @entity68 levels in the cerebral tissue following @entity932 . Our study intends to explore the role of magnetic resonance imaging (MRI) in establishing @entity68 levels in cerebral tissue at the periphery of the @entity1410 following an @entity932 . Initially, an MRI phantom was constructed with varying concentrations of liquid @entity68 preparation in a water bath container. Susceptibility weighted sequences were utilized to scan this phantom to generate T2* signal magnitude measurements corresponding to the @entity68 concentration in the phantom. Encouraged by the reliability of the measurements on the phantom, @entity1 with @entity932 were then recruited into this experimental study once the inclusion criteria were met. One control and two @entity1 subjects had their brains scanned in a 3 T MRI scanner utilizing the same susceptibility weighted sequence. We found that @entity932 perihematomal brain tissue @entity68 susceptibility signal measurements were 4 times higher than those of the baseline control and normal contralateral brain tissue. Three different baseline measurements (one control and two contralateral normal brain) revealed a level of 0.1 mg/ml of @entity68 concentration in the contralateral brain tissue in the identical anatomical location as the @entity1410 , typically in the basal ganglia region. T2 * signal measurements in the brain tissue at the periphery of the basal ganglia @entity1410 at day 7 following @entity548 revealed @entity68 concentration of 0.4 mg/ml (approximately 4 times the baseline/control) in two @entity1 subjects included in the study. These measurements mimic those obtained in published animal @entity932 model studies.
